Tuttiquotidiani is completely free. Every day we aggregate news from 100+ sources and generate original AI summaries for you. Help us keep the service running with a small donation, or become TQ Pro for just €1/month.

Donate now TQ Pro - 1€/mo

The Nazi files shedding new light on family secrets

Party membership records are now searchable online. But, as many Germans are finding out, the archive poses more questions than it answers

The young Chinese choosing life in ‘ghost cities’

Financial Times

June 30, 2026

How the great wealth transfer is rattling Wall Street

Financial Times

June 30, 2026

Madrid: the growing pains of a superstar city

Financial Times

June 27, 2026

AI fuels record $200bn M&A boom in US power sector

Financial Times

June 29, 2026

Roche gets FDA priority review for Enspryng in thyroid eye disease

Posted on June 30, 2026
By Bing News
0 Views
1 min read

Roche gets FDA priority review for Enspryng in thyroid eye disease

Roche RHHBY announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking label expansion of Enspryng (satralizumab) for the treatment of thyroid eye disease (TED). Enspryng is a humanized monoclonal antibody that targets IL-6, a key chemical messenger involved in the body's inflammatory response. The drug is currently approved in several countries for neuromyelitis optica...